The $12 Billion Battle At Pharma’s Bleeding Edge - Matthew Herper - The Medicine Show - Forbes
Links shared publicly online about this topic.
- 867total visits
The $12 Billion Battle At Pharma’s Bleeding Edge - Matthew Herper - The Medicine Show - Forbes
View full resource at blogs.forbes.com
Tags: Cholesterol, Bleeding, Depression, Drug, Pharma, Healthy Aging, Medical
Most Recently Shared on September 17, 2010 at 4:39 pm By:
The $12 Billion Battle At Pharma's Bleeding Edge: On Monday, things start getting hot for a trio of drugs tha... http://bit.ly/9yfp7S #drug
Amgen buys Micromet for $1.2 billion | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on January 27, 2012 at 10:38 am By:
Pharmafocus Health News and Pharma
Amgen buys Micromet for $1.2 billion - http://t.co/23TlBBvN
Merck - Top 10 pharma layoffs of 2011 - FiercePharma
fiercepharma.com — “Company: Merck ($MRK) Based: Whitehouse Station, NJJobs cuts announced: 12,000 to 13,000Date revealed: July 29Themes: Reducing costs, patent cliff The scoop: Merck's big plan to shed $1.5 billion in Read more...” View full resource at fiercepharma.com
Most Recently Shared on January 6, 2012 at 4:54 pm By:
In case you haven't seen, our ranking of pharma's top 10 layoffs last year, with Merck at the top http://t.co/QhBT7som #pharma #layoffs
Spain's new rules shut out off-patent brands - FiercePharma
fiercepharma.com — “The shape of Spain's pharmaceutical cuts is growing clearer. The government has approved new rules aimed at boosting generics use--and cutting €2.4 billion ($3.46 billion) from its drug spending Read more...” View full resource at fiercepharma.com
Most Recently Shared on August 24, 2011 at 5:30 pm By:
Spain's new drug-spending rules shut out off-patent brands. So, how much will they hurt Lipitor? http://t.co/Olu12XL $PFE
Merck plan to cut 12K more jobs aims to save $1.5B - FiercePharma
fiercepharma.com — “Merck's announcement of $2 billion in profits for the second quarter came with some more dispiriting news for the rank-and-file. The company plans to slash its workforce by another 12,000 to 13,000 Read more...” View full resource at fiercepharma.com
Most Recently Shared on July 29, 2011 at 5:00 pm By:
WIll new Merck cost cuts and layoffs help finance continued R&D push? http://bit.ly/nFQKFF
Novartis Q2 shines on new meds, cost cuts - FiercePharma
fiercepharma.com — “Novartis ($NVS) kicked off Big Pharma's earnings release with a nice surge in profits. Sales grew by 27% to $14.9 billion, including an 8% increase at the pharma unit. Profits rose by 12%. The strong Read more...” View full resource at fiercepharma.com
Most Recently Shared on July 19, 2011 at 3:22 pm By:
Novartis Q2 shines on new meds, cost cuts. http://bit.ly/o1nth4
Takeda denies $12bn Nycomed takeover reports | InPharm
inpharm.com — “Japan--™s biggest pharma firm Takeda denies reports it is negotiating a billion dollar deal to acquire Swiss speciality firm Nycomed” View full resource at inpharm.com
Most Recently Shared on May 13, 2011 at 10:11 am By:
Pharmafocus Health News and Pharma
Takeda denies $12bn Nycomed takeover reports http://goo.gl/fb/pPyIb
Takeda seeks global reach with $12 billion Nycomed bid | Reuters
reuters.com — “TOKYO/LONDON (Reuters) - Japan's largest drugmaker Takeda Pharmaceutical is in talks to buy privately-held Swiss rival Nycomed for more than $12 billion in a bid to extend its global reach into Europe” View full resource at reuters.com
Most Recently Shared on May 12, 2011 at 12:35 pm By:
Richard G. Lanzara Health Professional
Takeda offers $12 billion for drugs firm Nycomed: sources | Reuters http://t.co/r8l5EyJ via @reuters #Pharma #BioTech
Pfizer, Temasek to invest in Shanghai Pharma's $1.2bln IPO-paper | Reuters
reuters.com — “HONG KONG, May 3 (Reuters) - Shanghai Pharmaceuticals Co Ltd , China's second largest pharmaceutical productsdistributor, has secured four cornerstone investors for its $1.2billion Hong Kong IPO, the” View full resource at reuters.com
Most Recently Shared on May 3, 2011 at 11:15 am By:
John Carroll Health Communicator
Pfizer joins small group injecting $600M into Shanghai Pharmaceuticals. http://reut.rs/lFowSo
Clinical Data hires reps for Viibryd launch - FiercePharma
fiercepharma.com — “Now that Clinical Data has an FDA approval in hand, it's gearing up to grab a piece of the $12 billion antidepressant market. The company is hiring sales reps and rolling out a marketing campaign to... Read more...” View full resource at fiercepharma.com
Most Recently Shared on January 26, 2011 at 2:50 pm By:
Clinical Data hires reps for Viibryd launch. http://bit.ly/i6Ap2l
Mexico's Type 2 Diabetes Market Will Exceed $1.2 Billion In 2014
medicalnewstoday.com — “Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the type 2 diabetes market in Mexico will grow to $1.22 billion” View full resource at medicalnewstoday.com
Most Recently Shared on November 16, 2010 at 6:05 pm By:
Mexico's Type 2 Diabetes Market Will Exceed $1.2 Billion In 2014 http://mnt.to/3MDK #diabetes
TEVA REPORTS RECORD THIRD QUARTER 2010 RESULTS - FiercePharma
fiercepharma.com — “TEVA REPORTS RECORD THIRD QUARTER 2010 RESULTS-- Record Third Quarter Sales of $4.3 Billion and Non-GAAP EPS of $1.30 -- -- Record Quarterly Cash Flow from Operations of $1.2 Billion and Free Cash... Read more...” View full resource at fiercepharma.com
Most Recently Shared on November 2, 2010 at 12:12 pm By:
TEVA REPORTS RECORD THIRD QUARTER 2010 RESULTS. http://bit.ly/b4LoFj
The Associated Press: Endo Pharma paying $1.2 billion for Qualitest
google.com — “The Associated Press: Endo Pharma paying $1.2 billion for Qualitest” View full resource at google.com
Most Recently Shared on September 28, 2010 at 1:07 pm By:
AP: Endo Pharma paying $1.2 billion for Qualitest. http://bit.ly/acRoCu
The $12 Billion Battle At Pharma’s Bleeding Edge - Matthew Herper - The Medicine Show - Forbes
blogs.forbes.com — “On Monday, things start getting hot for a trio of drugs that could be the pharmaceutical industry's salvation. Drug companies have struggled to replace the aging cholesterol, blood pressure, and depression treatments that were once their best sellers, and retreated into high cost specialty medicines for rare diseases. But there is [...]” View full resource at blogs.forbes.com
Most Recently Shared on September 17, 2010 at 6:50 pm By:
Great @matthewherper article on coming #warfarin repl. RT @paliodoc: #anticoagulation for #afib w/o #coumadin is close http://bit.ly/a2rsTr
AstraZeneca's New Depression Drug Is a Cancelled Blood Pressure Medicine | BNET Pharma Blog | BNET
industry.bnet.com — “AstraZeneca (AZN)’s $1.2 billion deal with Targacept (TRGT) was for a new depression drug, TC-5214, but did you know that Targacept at one point” View full resource at industry.bnet.com
Most Recently Shared on December 8, 2009 at 8:26 pm By:
Jim Edwards Health Communicator
AstraZeneca's New Depression Drug Is a Cancelled Blood Pressure Medicine: AstraZeneca (AZN)’s $1.2 billion deal w... http://bit.ly/5hDMOA
Advertisement
